UCB is a leading biopharmaceutical company headquartered in Brussels, Belgium. The company has a strong focus on research and development, with a mission to transform the lives of people living with severe diseases. UCB operates in the biotech sector, which is a rapidly growing industry that involves the use of living organisms and biological processes to develop new drugs and therapies.

One of the key challenges facing the biotech sector, and indeed all industries, is the need to decarbonise and reduce greenhouse gas emissions. UCB recognises the importance of this challenge and has taken steps to reduce its environmental impact. The company has set ambitious targets to reduce its carbon footprint, including a commitment to become carbon neutral by 2030.

To achieve this goal, UCB has implemented a range of initiatives focused on corporate energy and renewable energy. The company has invested in energy-efficient technologies and processes to reduce its energy consumption and has also implemented a corporate power purchase agreement (PPA) to source renewable energy. A PPA is a long-term contract between a company and a renewable energy provider, which guarantees the purchase of a certain amount of renewable energy over a specified period.

UCB's corporate PPA is an important part of its decarbonisation strategy. The company has signed a 10-year agreement with ENGIE, a leading renewable energy provider, to purchase 55 GWh of renewable energy per year. This is equivalent to the annual energy consumption of around 15,000 households and will reduce UCB's carbon footprint by over 15,000 tonnes of CO2 per year.

The renewable energy will be sourced from two wind farms in Belgium, which will provide UCB with a reliable and sustainable source of energy. The PPA will also help to support the growth of renewable energy in Belgium, creating jobs and boosting the local economy.

In addition to its corporate PPA, UCB has also implemented a range of other initiatives to reduce its environmental impact. The company has invested in energy-efficient lighting, heating and cooling systems, and has implemented a range of measures to reduce waste and increase recycling. UCB has also set up an internal carbon pricing system, which encourages employees to consider the environmental impact of their decisions and actions.

UCB's commitment to decarbonisation and renewable energy is not only good for the environment, but also makes good business sense. The company's focus on sustainability and corporate responsibility has helped to build a strong reputation and attract new customers and investors. UCB's decarbonisation efforts have also helped to reduce its operating costs, making the company more competitive and resilient in the face of changing market conditions.

In conclusion, UCB is a leading biopharmaceutical company based in Belgium that operates in the biotech sector. The company has a strong focus on research and development and is committed to transforming the lives of people living with severe diseases. UCB recognises the importance of decarbonisation and has implemented a range of initiatives focused on corporate energy and renewable energy. The company's corporate PPA is an important part of its decarbonisation strategy, providing a reliable and sustainable source of renewable energy. UCB's commitment to sustainability and corporate responsibility has helped to build a strong reputation and attract new customers and investors, while also reducing its operating costs and increasing resilience.